Diabetes

Top Story

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

November 18, 2017

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.

The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers aimed to prevent type 2 diabetes and cardiovascular disease.

In the Journals

Nearly 1 in 7 patients with diabetes have poor glycemic control

November 17, 2017
About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient…
In the Journals PlusPerspective

Heart failure strongest predictor of poor survival in type 2 diabetes

November 17, 2017
Older adults with type 2 diabetes are at increased risk for death from cardiovascular complications, with the strongest associations found between survival and heart…
In the Journals Plus

Glycemic control, drug regimen interaction influence mortality risk in type 2 diabetes

November 17, 2017
Adults with type 2 diabetes who achieve low HbA1c targets may have an increased risk for death, particularly when treated with regimens associated with hypoglycemia…
More Headlines »
CME

Early Treatment of Diabetic Retinopathy and Diabetic Macular Edema: Optimal Use of Anti-VEGF Therapy for Vision Preservation and Restoration

This activity is supported by an educational grant from Genentech, Inc.

Diabetic retinopathy (DR) and diabetic macular edema (DME) are 2 of the most common causes of blindness among…
More »
Video
Meeting News

VIDEO: Heart failure most deadly complication of type 2 diabetes

July 16, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CME

Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Approximately 150 million people worldwide have diabetes mellitus and this number is expected to double by 2025…
More »
Advertisement
Advertisement